medigraphic.com
ISSN 1561-3038 (Print)

2015, Number 3

<< Back Next >>

Rev Cubana Med Gen Integr 2015; 31 (3)

Chronic Kidney Disease: prevent, rather than treat

Bencomo RO

Language: Spanish
References: 28
Page: 353-362
PDF size: 128.71 Kb.


ABSTRACT

Introduction: Chronic kidney disease has high prevalence. Usually it is easy to recognize and there are some treatments that can prevent its development and slow its progression to end-stage. It is defined as a set of heterogeneous diseases that affect renal structure and function. It is classified according to stages of severity, defined by glomerular filtration in addition to the clinical diagnosis.
Objective: Demonstrate the importance of primary health care (PHC) in preventing chronic kidney disease.
Methods: For updating the literature, a search was conducted in databases such as Medline Complete and Medline with Full Text in Ebsco, Pubmed and Scielo regional. All primary studies or literature reviews where chronic kidney disease was the center of attention were considered.
Conclusions: Strengthening programs of primary health care, with an emphasis on slowing renal damage is necessary. Chronic kidney disease is a health problem that potentiates the importance of interdisciplinary work, social contribution, the participation of people in their own health care, institutionalization of preventive programs and a higher level of cooperation between the health teams for preventing and delaying chronic kidney disease. Simple and inexpensive actions compared to dialytic treatment and loss of health, high costs, both economic and social involving both diagnosis and treatment, as well as the high incidence of complications demonstrated in this disease determine prevention is the crucial point to stop its spread.


REFERENCES

  1. Egocheaga MI, Lobos JM, Guissasola FA, Alcázar R, Orte L, Parra EG, et al. Documento de consenso sobre la enfermedad renal crónica. Sociedad Española de Nefrología (SEN). Sociedad Española de Medicina de Familia y Comunitaria (semFYC). Barcelona: semFYC Ediciones; 2007.

  2. K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.

  3. Lorenzo V, Perestelo L, Barroso M, Torres A, Nazco J. Economic evaluation of haemodialysis. Analysis of cost components based on patient specific data. Nefrologia 2010;30(4):403-12.

  4. Pérez Oliva JF. Anuario de la enfermedad renal crónica. Cuba; 2012 [citado Feb 2015]. Disponible en: http://files.sld.cu/nefrologia/files/2013/06/anuario-nefrologia- 2012.pdf .

  5. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012;379(9811):165-80.

  6. KDIGO 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013;3(Suppl 1):1-308.

  7. Otero A, de FA, Gayoso P, Garcia F. Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrología 2010;30(1):78-86.

  8. Klahr S, Levey AS, Beck GJ. The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330(13):877-84.

  9. Alcazar R, Egocheaga MI, Orte L. SEN-SEMFYC consensus document on chronic kidney disease. Nefrología 2008;28(3):273-82.

  10. House AA, Ronco C. The burden of cardiovascular risk in chronic kidney disease and dialysis patients (cardiorenal syndrome type 4). Contrib Nephrol. 2011;171:50-6.

  11. Lou Arnal LM, Campos Gutiérrez B, Boned Juliani B, Turón Calzado JM, Gimeno Orna JA. Estimación del filtrado glomerular en atención primaria: prevalencia de enfermedad renal crónica y repercusión sobre la derivación a nefrología. Nefrología 2008 [citado Feb 2015];28(3):329-32. Disponible en: http://www.revistanefrologia.com/revistas/P1-E28/P1-E28-S289-A477.pdf

  12. Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis 2009;53(3 Suppl 3):S4-16.

  13. Norma Oficial Mexicana “Para la prevención, tratamiento y control de la diabetes mellitus”. NOM-015-SSA2-2010.: Secretaría de Salud; 2010 [citado Feb 2015]. Disponible en: http://dof.gob.mx/nota_detalle.php?codigo=5168074&fecha=23/11/2010

  14. Góngora-Ortega J, Serna-Vela F, Gutiérrez-Mendoza I, Pérez-Guzmán C. Prevalencia de enfermedad renal crónica en niños de Aguas calientes, México. Salud Pública México 2008 [citado Feb 2015];50(6):436-7. Disponible en: http://www.scielosp.org/scielo.php?pid=S0036- 36342008000600002&script=sci_arttext

  15. Guía de Práctica Clínica Prevención, Diagnóstico y Tratamiento de la Enfermedad Renal Crónica Temprana, México: Secretaría de Salud; 2009 [citado Feb 2015]. Disponible en: http://www.cenetec.salud.gob.mx/interior/gpc.html

  16. Crowe E, Halpin D, Stevens P. Early identification and management of chronic kidney disease: summary of NICE guidance. BMJ 2008;337:a1530.

  17. Brosius FC III, Hostetter TH, Kelepouris E. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. Circulation 2006;114(10):1083-7.

  18. Gracia-García S, Montanes-Bermudez R, Morales-García LJ. Current use of equations for estimating glomerular filtration rate in Spanish laboratories. Nefrologia 2012;32(4):508-16.

  19. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-54.

  20. Montanes-Bermudez R, García-García S. Use of estimated glomerular filtration formulas for dose adjustment. Nefrologia 2012;32(2):253-5.

  21. Mennini T. FDA draft guidance. Nutrafoods 2012 [citado Feb 2015];4(11):165. Disponible en: http//www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Gui dances/UCM204959.pdf

  22. Gregorio Tomás Obrador GT, Bourlón de los Ríos MT, Gómez MA, Laris A, Contreras D. Guías Latinoamericanas de Práctica Clínica sobre la Prevención, Diagnóstico y tratamiento de la Enfermedad Renal Crónica. México: Fundación Mexicana del Riñón; 2012.

  23. Miller WG, Bruns DE, Hortin GL. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009;55(1):24-38.

  24. National Collaborating Centre for Chronic Conditions. Chronic kidney disease: national clinical guideline for early identification and management in adults in primary and secondary care. London: Royal College of Physicians; 2008.

  25. Navaneethan SD, Aloudat S, Singh S. A systematic review of patient and health system characteristics associated with late referral in chronic kidney disease. BMCNephrology 2008;9:3. doi:10.1186/1471-2369-9-3.

  26. Campbell KH, Smith SG, HemmerichJ, Stankus N, Fox C, Mold JW et al. Patient and provider determinants of nephrology referral in older adults with severe chronic kidney disease: a survey of provider decision-making. BMC Nephrology 2011;12:47.

  27. Goergen SK. Systematic review of current guidelines, and their evidence base, on risk of lactic acidosis after administration of contrastmedium for patients receiving metformin. Radiology. 2010;254:261-9.

  28. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High dose N-acetylcysteine for the prevenetion of contrast-induced nephropathy. Am JMed. 2009;122:874-9.




2020     |     www.medigraphic.com